Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Genentech’s Xofluza Approved for People at High Risk of Developing Flu-Related Complications

Genentech’s flu medication Xofluza won a new indication for the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for less than 48 hours and are at high risk of flu-related complications.

Read More »

CSL Behring, Pharming Group Embroiled in Intellectual Property Lawsuit

Netherlands-based Pharming Group N.V. denied any involvement in a potential theft of intellectual property belonging to CSL Behring from Joseph Chiao, who recently joined Pharming as medical director.

Read More »

The Use of NLP to Improve Phenotype Extraction for Precision Medicine

In this webinar, Dr. Benjamin Darbro and Alyssa Hahn will discuss how their organization is using Natural Language Processing to transform unstructured source data into clinical and research decision support insights.

Read More »

FDA Approves Noven Pharmaceuticals’ Transdermal Patch for Schizophrenia

Noven Pharmaceuticals won approval from the U.S. Food and Drug Administration for the company’s transdermal schizophrenia patch.

Read More »

Research Points to Inconsistent Use of Patient Experience Data in FDA Approvals

Sanofi is pressing the U.S. Food and Drug Administration to keep the company’s patient experience data consistent following a review of approved applications required by the 21st Century Cures Act.

Read More »

Research Shows New Possibilities for PARP Inhibitors in Lung Cancer

Researchers from the University of Maryland School of Medicine (UMSOM) published data from a proof-of-concept study in the journal PNAS that showed combining a PARP inhibitor with a DNMT inhibitor was effective in treating non-small cell lung cancer tumors.

Read More »

Phase III PEMPHIX Study Shows Genentech’s Rituxan Superior to Mycophenolate Mofetil in Patients With PV

Genentech announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan compared to mycophenolate mofetil in adults with moderate to severe pemphigus vulgaris (PV).

Read More »

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib in Phase 3 Studies for Rheumatoid Arthritis

Gilead Sciences Inc. and Galapagos NV announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis (RA) – are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier during 2019.

Read More »

Datavant and Parexel Partner to Harness Real-World Evidence

Parexel will tap into real-world data to connect the biopharmaceutical services provider to data from the company’s clinical trials through a multi-year partnership with Bay Area-based Datavant.

Read More »

Adopting a Patient-Centric Approach to Ensure Safe and Effective Use

EVERSANA’s Jeffrey LaVaute discusses how patient centricity is a foundational principle that informs the healthcare decisions that we make.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom